Is Alpelisib-Piqray suitable for lung adenocarcinoma with pik3ca mutation?

Clinical guidelines generally recommend the combination of Alpelisib-Piqray and fulvestrant in postmenopausal women and men with hormone receptor-positive, HER-2-negative, PIK3CA-mutated advanced or metastatic breast cancer who have received prior endocrine therapy (eg, aromatase inhibitors with or without cyclin-dependent kinase [CDK] 4/6 inhibitors).

Apelix is aPIK3CA inhibitor used to treat breast cancer with PIK3CA mutations. At present, clinical studies of Apelvis in the field of breast cancer have achieved some positive results, but there are relatively few studies in the field of lung adenocarcinoma. Although PIK3CA mutations are present in some patients with lung adenocarcinoma, further research and clinical trials are needed to determine the safety and effectiveness of Apelvis in this setting. Therefore, whether patients with lung adenocarcinoma can use Apellis requires detailed discussion with a lung cancer specialist or medical team. The patient's individual situation, genetic variation and other related factors may be evaluated to determine whether Apelis is suitable as a treatment option for lung adenocarcinoma.

The original drug of Apellis is not marketed in the country and therefore cannot be included in medical insurance. There are European and Indian versions of the original Apelvis drug sold overseas. The ingredients are basically the same. The price of the European version of 150mg*56 tablets per box may be more than 4 RMB 40,000 ( (The price may fluctuate due to the exchange rate), The price of the Indian version150mg*28 tablets per box may be more than 5,000 yuan (the price may fluctuate due to the exchange rate). There are currently no generic versions of Apelvis produced and marketed.